# Pivotal Bioequivalence Study of Exemestane 25 mg Tablets Under Fasting Conditions in Healthy Subjects

> **NCT01760980** · PHASE1 · WITHDRAWN · sponsor: **Actavis Inc.**

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Reference product (A) Aromasin (Exemestane)
- **DRUG:** Test product (B) Exemestane

## Key facts

- **NCT ID:** NCT01760980
- **Lead sponsor:** Actavis Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-11
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Development halted by management
- **Last updated:** 2019-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01760980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01760980, "Pivotal Bioequivalence Study of Exemestane 25 mg Tablets Under Fasting Conditions in Healthy Subjects". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01760980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*